Skip to main content

Table 1 Baseline characteristics of anaplastict thyroid cancer (ATC) patients treated with pembrolizumab added as a salvage therapy to kinase inhibitor therapy

From: Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma

  N = 12
Median Age at treatment start, years (range) 60 (47–84)
Gender, n (%)
 Men
 Women
8 (67)
4 (33)
Ethnicity, n (%)
  Caucasian
  Asian
  Black
9 (75)
2 (16)
1 (9)
Stage at Diagnosis, n (%)
  IVA
  IVB
  IVC
0 (0)
3 (25)
9 (75)
Pathology, n (%)
  ATC only
  Papillary thyroid cancer + ATC
  Poorly differentiated thyroid cancer + ATC
  Follicular thyroid cancer +ATC
4 (33)
4 (33)
3 (25)
1 (9)
PD-L1 status, n (%)
  < 10%
 11–50%
 51–100%
10 (83)
2 (20)
4 (40)
4 (40)
Performance Status, n (%)
  ECOG 0
  ECOG 1
  ECOG 2
2 (16)
6 (50)
4 (33)
Previous Treatment for ATC, n (%)a
  Surgery, n (%)
  Radiation/chemosensitizing, n (%)
  Bridging Chemotherapy, n (%)b
5 (41)
6 (50)
3 (25)
Targeted therapyc, n (%)
  Lenvatinib
  Dabrafenib + trametinib
  Trametinib alone
5 (41)
6 (50)
1 (9)
  1. aPatients received more than 1 modality of therapy
  2. bChemotherapy as a bridging therapy while awaiting targeted therapy
  3. cAll patients with BRAFV600E mutations were treated with dabrafenib + trametinib